Dr. David Portman is the Founder and Director Emeritus of the Columbus Center for Women’s Health Research as well as Adjunct Instructor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine. Dr. Portman has conducted over 100 clinical studies in sexual dysfunction, menopause, hormone and SERM therapy, contraception and other issues pertaining to women’s health. He has published dozens of articles in numerous peer-reviewed medical journals including the American Journal of Obstetrics and Gynecology, Menopause, Journal of Sexual Medicine, Obstetrics and Gynecology, and Contraception and presented his research at conferences nationally and internationally.
Dr. Portman is a previous member of the Board of Directors of the International Society for the Study of Women’s Health (ISSWSH) and ISSWSH Fellow. He is also an active member of the North American Menopause Society, International Menopause Society, International Society for Sexual Medicine, and ISSWSH. Dr. Portman was Co-Chair of the ISSWSH/NAMS 2013 Genitourinary Symptom Nomenclature Consensus Conference.
He received his BA from Northwestern University and his MD from The Ohio State University College of Medicine where he also completed his residency in Ob/Gyn.
Dr. Portman was a principal investigator for the flibanserin, bremelanotide, and Intrarosa pivotal trials, and presented the efficacy data to the FDA Advisory Committee around the approval of Addyi and he continues to consult and lecture widely on sexual dysfunction, menopause, and other areas of women’s health.
He is currently CEO at Sermonix Pharmaceuticals developing drugs for the treatment of advanced breast cancer.